Steven M. Fruchtman
Net Worth

Last updated:

What is Steven M. Fruchtman net worth?

The estimated net worth of Dr. Steven M. Fruchtman is at least $7,788,960 as of 7 Feb 2024. He has received compensation worth at least $7,788,960 in Onconova Therapeutics, Inc..

What is the salary of Steven M. Fruchtman?

Dr. Steven M. Fruchtman salary is $865,440 per year as Chief Executive Officer, Pres & Director in Onconova Therapeutics, Inc..

How old is Steven M. Fruchtman?

Dr. Steven M. Fruchtman is 74 years old, born in 1951.

What stocks does Steven M. Fruchtman currently own?

As insider, Dr. Steven M. Fruchtman owns shares in one company:

Company Title Shares Price per share Total value
Onconova Therapeutics, Inc. (ONTX) Chief Executive Officer, Pres & Director 18,130 $0 $0

What does Onconova Therapeutics, Inc. do?

Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer. It has two clinical-stage programs, including narazaciclib (ON 123300), a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies as a single agent or in combination with other anti-cancer therapies; and oral rigosertib alone or in combination with PD-1 inhibitor, which is in Phase I/IIa for the treatment of progressive K-Ras mutated non-small cell lung cancer. The company develops a Phase Ib/II ISS with rigosertib monotherapy in patients with advanced squamous cell carcinoma associated with recessive dystrophic epidermolysis bullosa; and has a preclinical program comprising IV/oral rigosertib for COVID-19. It has a license agreement with SymBio Pharmaceuticals Limited; license, development, and commercialization agreement with Pint International SA.; and a license and collaboration agreement with HanX Biopharmaceuticals, Inc. for the development, registration, and commercialization of narazaciclib. Onconova Therapeutics, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.

ONTX logo
ONTX
Onconova Therapeutics, Inc.

Steven M. Fruchtman insider trading

Onconova Therapeutics, Inc.

Transaction Date Security Shares Price per share Total value Source
Option
Common Stock 21,320 N/A N/A
Option
Restricted Stock Units 21,320 N/A N/A
Option
Common Stock 12,567 N/A N/A
Option
Restricted Stock Units 12,567 N/A N/A
Option
Restricted Stock Units 21,320 N/A N/A
Option
Common Stock 21,320 N/A N/A
Option
Restricted Stock Units 12,566 N/A N/A
Option
Common Stock 12,566 N/A N/A
Purchase
Common Stock 2,381 $4.2 $10,000
Purchase
Common Stock 20,000 N/A N/A
Purchase
Common Stock 40,000 N/A N/A
Purchase
Common Stock 26,800 N/A N/A
Purchase
Warrant (right to purchase) 149,000 N/A N/A
Purchase
Common Stock 149,000 N/A N/A
Option
Stock Option (right to buy) 100 N/A N/A
Option
Common Stock 100 N/A N/A

Onconova Therapeutics key executives

Onconova Therapeutics, Inc. executives and other stock owners filed with the SEC:

  • Dr. Steven M. Fruchtman (74) Chief Executive Officer, Pres & Director
  • Mr. Mark Patrick Guerin CPA (56) Chief Financial Officer